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Abstract
Background: Differential expression of perforin (PRF1), a gene with a pivotal role in immune
surveillance, can be attributed to differential methylation of CpG sites in its promoter region. A
reproducible method for quantitative and CpG site-specific determination of perforin methylation
is required for molecular epidemiologic studies of chronic diseases with immune dysfunction.
Findings: We developed a pyrosequencing based method to quantify site-specific methylation
levels in 32 out of 34 CpG sites in the PRF1 promoter, and also compared methylation pattern in
DNAs extracted from whole blood drawn into PAXgene blood DNA tubes (whole blood DNA)
or DNA extracted from peripheral blood mononuclear cells (PBMC DNA) from the same normal
subjects. Sodium bisulfite treatment of DNA and touchdown PCR were highly reproducible
(coefficient of variation 1.63 to 2.18%) to preserve methylation information. Application of
optimized pyrosequencing protocol to whole blood DNA revealed that methylation level varied
along the promoter in normal subjects with extremely high methylation (mean 86%; range 82–92%)
in the distal enhancer region (CpG sites 1–10), a variable methylation (range 49%–83%) in the
methylation sensitive region (CpG sites 11–17), and a progressively declining methylation level
(range 12%–80%) in the proximal promoter region (CpG sites 18–32) of PRF1. This pattern of
methylation remained the same between whole blood and PBMC DNAs, but the absolute values
of methylation in 30 out of 32 CpG sites differed significantly, with higher values for all CpG sites
in the whole blood DNA.
Conclusion:  This reproducible, site-specific and quantitative method for methylation
determination of PRF1 based on pyrosequencing without cloning is well suited for large-scale
molecular epidemiologic studies of diseases with immune dysfunction. PBMC DNA may be better
suited than whole blood DNA for examining methylation levels in genes associated with immune
function.
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Background
Perforin (PRF1), a major immune surveillance gene, is a
candidate gene for the identification of methylation mark-
ers, and for investigating the pathophysiology of a
number of chronic diseases with suspected immune dys-
function [1-9]. Earlier studies to assess PRF1 promoter
methylation used bisulfite sequencing of cloned PCR
products [5]. Cloning PCR products for quantitative site-
specific determination of CpG methylation is laborious,
and can be inaccurate due to under-representation of the
number of clones analyzed. On the other hand, pyrose-
quencing technology offers a convenient way for quanti-
tative site-specific determination of CpG methylation but
this technology has not yet been developed for the study
of PRF1. Pyrosequencing determines the ratio of C/T base
changes after bisulfite treatment, reflecting the proportion
of unmethylated and methylated cytosines at each CpG
site in the original sequence [10].
Several factors like sample collection, bisulfite treatment,
and PCR can affect the reproducibility of methylation lev-
els determined by pyrosequencing. Blood is a non-inva-
sive source of sample for molecular epidemiologic
studies. Usually, blood is drawn into blood collection
tubes followed by separation of peripheral blood mono-
nuclear cells (PBMCs) to extract DNA for molecular
genetic studies including methylation. Recently, to mini-
mize variability in primary blood samples from multi-
center studies and to enable transport and storage, blood
is drawn into specialized tubes like PAXgene blood DNA
tubes containing additives for cell lysis. These PAXgene
blood DNA tubes are then transported to laboratories
where DNA is extracted directly from the whole blood
without PBMC separation. DNA extracted from PAXgene
blood DNA tubes thus represents the contribution of all
blood cell types and have been successfully used for gen-
otyping. However, the impact of these blood collection
procedures for DNA (whole blood vs PBMC DNA) on
methylation levels has not been reported.
In this study, we developed a pyrosequencing based meth-
ylation assay for a total of 32 out of 34 CpG sites in the
promoter region of PRF1. The assay is highly reproducible
with respect to bisulfite treatment, and PCR. Examination
of methylation levels in normal subjects showed that
methylation levels differ significantly between DNAs
extracted from PBMCs and whole blood for all 32 CpG
sites except two, although the methylation pattern
remained similar over the 1.4 kb promoter region. These
results show that site-specific assessment of CpG methyl-
ation in PRF1 can be reproducibly assessed by pyrose-
quencing without cloning, and that PBMC DNA may be
better suited than whole blood DNA for molecular epide-
miologic studies on methylation levels of genes associated
with immune dysfunction.
Methods
Pyrosequencing strategy
Bisulfite converted sequences were simulated by a previ-
ously reported Microsoft Word bisulfite macro [11] fol-
lowed by pyrosequencing assay design using Assay Design
Software (Biotage, Uppsala, Sweden). Both top and bot-
tom strands were used for designing primers to cover all
the 34 CpG sites in 1.4 kb PRF1 promoter. Similarly, both
forward and reverse sequencing designs were employed
with 5'biotinylation of the reverse or forward PCR primer
respectively. All primers were synthesized at the Biotech-
nology Core Facility, Centers for Disease Control & Pre-
vention, Atlanta, GA.
DNA samples and bisulfite treatment
Blood drawn in PAXgene blood DNA tubes (Qiagen, CA)
for DNA extraction were obtained from 20 subjects who
took part in the Chronic Fatigue Syndrome Study at the
Centers for Disease Control and Prevention, Atlanta, GA.
From five of these subjects classified as normal, blood was
also drawn in BD Vacutainer CPT tubes (BD, NJ) followed
by separation of PBMC for DNA extraction. DNA from
PAXgene blood tubes was extracted using PAXgene blood
DNA kit (Qiagen) whereas DNA from PBMCs was
extracted using Roche DNA isolation kit for mammalian
blood (Roche Applied Science, IN). DNA was quantified
using NanoDrop ND-100 Spectrophotometer (Thermo
Fisher Scientific, MA) prior to bisulfite treatment. DNA
(200 ng/reaction) was bisulfite treated using the EZ DNA
Methylation Kit (Zymo Research, CA), according to the
manufacturer's instructions. Bisulfite treated DNA (BST-
DNA) was eluted twice in 10 μl of the manufacturer's M-
Elution Buffer (20 μl final volume), and was stored in
aliquots at -20°C until use.
PCR and pyrosequencing
Each 100 μl PCR contained 1.5 mM MgCl2, 0.2 mM dNTP,
0.05 U/μl Platinum Taq DNA polymerase (Invitrogen,
CA) and 0.2 μM each of forward and reverse primers
(Table 1) and 5 μl of BST-DNA. In this study, we used a
touchdown PCR cycling approach previously reported for
BST-DNA [12] for all amplicons except amplicon F (Table
1). Touchdown PCR consisted of one cycle of 94°C for 5
min for the initial denaturation step. This was followed by
5 cycles each of denaturation at 94°C for 30 s, varying
annealing for 30 s, and extension at 72°C for 30 s. Anneal-
ing temperatures for the touchdown portion were pro-
vided as follows: 65°C for 5 cycles, 62°C for 5 cycles,
59°C for 5 cycles, 56°C for 5 cycles and 52°C for 5 cycles.
A further 50 cycles constituted the following: 94°C for 30
s, 50°C for 30 s and 72°C for 30 s. PCR was terminated
after a final cycle at 72°C for 7 min. PCR cycling condi-
tions for amplicon F consisted of the following: one cycle
of 95°C for 2 min; 50 cycles of 95°C for 15 s, 52°C for 30
s, 72°C for 30 s; one cycle of 72°C for 5 min.B
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Table 1: Primer sets for determination of perforin CpG methylation by pyrosequencing
Amplicon*
(bp)
PCR primers† (5' to 3') Sequencing primers‡ CpG site # and nucleotide
position∞
A (236) FW: TTG ATT TTA TAG GTG AGG AAA TTA
RV: TTC CAA CTA TCA CCC ATA ACC TAA
TTT TAT AGG TGA GGA AAT TA
AYGTTTAGAAAGGGGGTTGATATTTATYGTYGTGAGGTATAYGG
ATT TTT ATG TTT TTT AAA T
YGGTTTTTTTGTTA
1, -1365; 2, -1339; 3, -1336; 4, -1325
6, -1231
B (226) FW: ATG TTG AGG TTG TGA GGA GTT TT
RV: AAA TTC CAA AAT CCT CTC TTT AAT
GAA GTT TTG TAA AGT ATT TG
YGGGAAAAGAG
5, -1267
C (196) FW: TTG GAA AGT GAT TAG GAG GTT GTA
RV: CAA ACT CCA AAC CAC ATA TAA CAT
AGA GGG TGG GGA TATT
GYGGAGAGAAGATGGGGTTAGATTTYG
GTT TTT GTT TTT GTA AGA GT
AGGGAYGGAAGTAGGGATATAAAYG
7, -1110; 8, -1088
9, -1045; 10, -1027
D (91) FW: GAG GTT TTT ATG GGT GGA GTG AT
RV:CAC CTC CTC CCT TAC CCA ACT A
TTG GGG GGT AAA ATT
ATAYGGTTTT T
11, -876
E (256) FW: TTT TGA GTG GGA GAA GAG AGA TGT
RV:CCC CAC CCT AAC CTC AAA CA
GTG AGA GTG GTT TGG TAG
TATYGGAGG
TTG GTT TTA GTT TTG TTG A
GGTYGTGGGT
AGG ATA GTT AGT GGT TTT TA
YGTTGGTTTTAGTTTTGTTG
12, -776
13, -774
14, -720
F (167) FW: TGG AGG TTA TTG GTT GTT TTT ATA
RV: TAA CCA TTC CCT CCT CCC TAA ATA
GGT TAT TGG TTG TTT TTA TA
AAGYGAGGAGTAGGAGTTTTTGTTYGAGGAATATGTTTGGAGTTYGG
15, -691; 16, -670; 17, -650
G (300) FW: TTA GGG AGG AGG GAA TGG TTA TAG
RV: AAC CAA CAA AAC CAT CTC CTT ACT
TAG TTT ATA TTG TTG GTG TA
TAATYGAGTTGTTTAAGTTTYGGYGGTTTGGYG
18, -397; 19, -381; 20, -378; 21, -370
H (300) FW: TTT AGG GAG GAG GGA ATG GTT ATA
RV: ACC AAC AAA ACC ATC TCC TTA CTT
TAC TTC TAA TAC ACA ACA TC
RCATATATAAAATATAAAAAACAAACAAAAACRACRAC
24, -313; 23, -345; 22, -348
I (233) FW: GGG GAT TTA GGG TAT ATA GG
RV: AAA CCC TAC CAA TCC ACA CTA CT
GGG GAT TTA GGG TAT AT
AGGYGGAGGAGGGYGGGGYGTTGAGGATTTTGAGATTYGGT
28, -219; 27, -229; 26, -234; 25, -253
J (237) FW: TGG TTT TGT TGG TTT GTT TAT TAA
RV: CCC CAA CTA TAA TCA CAA ATC CTT
CAA AAC CAA AAA CTC ATC T
ACCRAATAAAACTACTAAAACTCR
CCT CAA CCC TCA TCC
RACTCCCCACTAACAACCCTCAAAAAACRAAC
30, -180; 29, -200
32, -122; 31, -150
K (97) FW: TTG AGG ATA GGG TGG GTG TT
RV: CCA CCA CTC ACA TCA CTT CTA CTT
GGA TAG GGT GGG TGT T
YGTGGGAGGGGAGAGTATAAAGGATTTGTGATTATAGTTGGGGGY
33, -92; 34, -48
*Nucleotide positions of amplicons from 5' → 3' direction of the top or bottom strand used for assay design. A, 20 – 255; B, 1186 – 1411; C, 250 – 445; D, 826 – 916; E, 569 – 824; F, 692 – 858; G, 
838 – 1137; H, 837 – 1136; I, 200 – 432; J, 1124 – 1360; K, 1298 – 1394. Amplicons in bold (B, D, E and I) represent those amplicons designed using the bottom strand after bisulfite conversion.
†Fw, forward primer; Rv, reverse primer. Biotinylated primers are indicated in bold.
†Sequencing primers are indicated in bold. Sequences to analyze are italicized with the CpG sites (Y or R) underlined.
∞Indicates CpG site number and corresponding nucleotide location from the distal end of the promoter. Numbering is based on the top strand used for assay design.BMC Research Notes 2009, 2:104 http://www.biomedcentral.com/1756-0500/2/104
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Pyrosequencing was performed according to the manufac-
turer's instructions. The PyroGold kit was used in con-
junction with the PSQ 96MA instrument (Biotage), and
each pyrosequencing reaction used 20 μl of PCR product.
Biotinylated single strand DNA was separated by immobi-
lizing the PCR product on streptavidin coated Sepharose
High Performance beads (Amersham Biosciences, NJ) and
strand separated by denaturation with 0.2 N NaOH. After
denaturation, the biotinylated strand was annealed to
sequencing primer (0.5 μM final concentration), and sub-
jected to sequencing using an automatically generated
nucleotide dispensation order for the "sequence to ana-
lyze" corresponding to each reaction (Table 1). Pyrograms
were analyzed in "Allele Quantification" mode in order to
determine the percentage of C/T, corresponding to the
percentages of methylated and unmethylated C at each of
the CpG sites. As a positive control for PCR and pyrose-
quencing, we used previously reported PCR and sequenc-
ing primers to detect two CpG sites in CDNK2A [13].
Assay reproducibility
1. Bisulfite reproducibility
The impact of bisulfite treatment on assay reproducibility
was tested using the PCR and pyrosequencing conditions
for CpG sites 18–21 in amplicon G with whole blood
DNA from 20 subjects. The same DNA was bisulfite
treated on three separate days. Each day, 20 individual
bisulfite reactions were set up with 200 ng DNA/reaction.
BST-DNA from each of the three days was simultaneously
subjected to PCR in the same thermocycler to eliminate
PCR-to-PCR variability. All PCR products were used for
pyrosequencing in duplicate, giving a mean of 6 pyrogram
readings per CpG site for all three sets of BST-DNA per
subject. Day-to-day variation in bisulfite reaction was
expressed as coefficient of variation (CV) calculated as the
percentage of standard deviation to its mean
2. Touchdown PCR reproducibility
The impact of PCR-to-PCR variability, expressed in terms
of CV, was also tested for CpG sites 18–21 in amplicon G
on three different days using the same BST-DNA. Touch-
down PCR reproducibility was done with whole blood
DNA from 10 subjects. Each PCR product was subjected to
pyrosequencing in duplicate, yielding a mean of 6 values
per CpG site for PCR from all three days per subject.
Evaluation of methylation pattern in the PRF1 by 
pyrosequencing
A small pilot study consisting of five normal subjects was
conducted to evaluate the robustness of the optimized
conditions to determine the methylation level/pattern in
the PRF1 promoter for 32 CpG sites. This pilot study also
examined the impact of DNA from whole blood or PBMC
on PRF1 methylation profile in normal subjects. For each
subject, two separate bisulfite reactions were set up, fol-
lowed by corresponding PCR and pyrosequencing reac-
tions yielding a mean of 2 values per CpG site. Both whole
blood and PBMC DNAs were treated similarly to generate
the PRF1 methylation profiles.
Results
The PRF1  promoter spans about 1.4 kb (-1411 to +1)
upstream of the transcriptional start site and harbors a
number of transcription factor binding sites [14,15]. Out
of a total of 34 CpG sites in the PRF1 promoter, 10 are in
the distal promoter region containing enhancer elements
(CpG sites 1–10), 17 are in the proximal promoter region
harboring repetitive elements (CpG sites 18–34), and
seven (CpG sites 11–17) are in the methylation sensitive
region (MSR) located between the distal and proximal
promoter regions (Figure 1). Eleven amplicons A to K and
16 sequencing primers were designed to cover all 34 CpG
sites (Figure 1; Table 1).
We compared the performance of PCR with single anneal-
ing temperature and touchdown PCR and found that PCR
cycling program with a single annealing temperature
often generated multiple bands, particularly with ampli-
con E, which is rich in AT content (70%). On the other
hand, touchdown PCR consistently generated specific
products of expected size with all amplicons except ampli-
con F, for which PCR with single annealing temperature
consistently resulted in specific product than touchdown
PCR. Thus, we used touchdown PCR to generate all ampli-
cons, except amplicon F which was generated with PCR
following single annealing temperature. Pyrosequencing
reactions for all CpG sites were successful except CpG sites
33 and 34 in amplicon K, although amplicon K was suc-
cessfully generated by the touchdown PCR.
Variability due to bisulfite treatment was tested for four
CpG sites (sites 18–21) in amplicon G using whole blood
DNA from 20 individual subjects. Variability due to
bisulfite treatment was found to be minimal for all four
CpG sites in amplicon G, (mean CV of 2.18%, and CVs for
individual CpG sites ranged from 1.97% to 2.37%, Figure
2). Variability due to touchdown PCR was also assessed
for CPG sites 18–21 using whole blood DNA from 10 sub-
jects and was found to be very low for all four CpG sites in
amplicon G, with a mean CV of 1.63%, and with CVs for
individual CpG sites ranging from 1.34% to 1.86% (Fig-
ure 3).
Application of the optimized conditions to generate PRF1
methylation profile for 32 CpG sites using whole blood
DNA from five normal subjects revealed that the methyl-
ation levels varied along the promoter with extremely
high methylation (mean 86%; range 82%–92%) in the
distal enhancer region covering CpG sites 1–10 (Figure 4).
Methylation levels in the MSR covering CpG sites 11–17BMC Research Notes 2009, 2:104 http://www.biomedcentral.com/1756-0500/2/104
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appeared to vary up and down from a low of 49% (CV =
1.49%) at CpG site 11 to a high of 83% (CV = 0.84%) at
CpG site 16 (mean methylation level for sites 11–17 =
67%). Interestingly, methylation levels in the proximal
promoter region covering CpG sites 18–32 progressively
declined from a high of 73–80% at sites 18–19 to as low
as 12–20% at sites 30 and 32 (mean methylation at sites
18–32 = 54%). Among specific sites, CpG sites 11, 15, 25,
29 and 30 showed sharp decline in methylation levels
compared to adjacent CpG sites. Perforin methylation
profile over the same 32 CpG sites in the same five sub-
jects using PBMC DNA appeared very similar i.e.,
extremely high methylation in the distal enhancer region,
a variable methylation in the MSR, and progressively
declining methylation in the proximal promoter region.
However, except for CpG sites 5 and 15, the absolute
methylation levels at each CpG site as determined from
the whole blood and PBMC DNAs differed significantly,
with higher values for all CpG sites in the whole blood
DNA (Figure 4).
Discussion
Analytical procedures for sensitive and site-specific quan-
titative determination of CpG methylation are influenced
by several factors, all of which require careful experimen-
tal optimization and validation before the assay can be
applied to valuable, and often limited clinical samples in
large-scale molecular epidemiologic studies. A number of
PCR-based methylation assays utilize bisulfite treatment
to preserve the methylation signature of the original DNA.
Bisulfite treatment selectively converts unmethylated
cytosines to uracil. This base modification results in
reduced sequence complexity, which often makes the
development of methylation assays difficult due to dimin-
ished flexibility in designing quality PCR and sequencing
primers, allele-specific PCR biases, and reduced signal
strength or abnormally shaped sequencing reactions
[16,17]. We considered these factors while developing a
pyrosequencing assay to determine the methylation status
of PRF1, an important gene in immune surveillance.
Pyrosequencing assay was designed for all 34 CpG sites in
the PRF1 promoter, of which seven CpG sites form a func-
tionally significant subset in the MSR of the promoter. We
successfully optimized several steps of the pyrosequenc-
ing technology to obtain highly reproducible methylation
levels for each of the 32 out of 34 CpG sites. Bisulfite treat-
ment resulted in minimal day-to-day variation (CV
The perforin (PRF1) promoter (1411 bp) with locations of 34 CpG and several putative transcription factor binding sites Figure 1
The perforin (PRF1) promoter (1411 bp) with locations of 34 CpG and several putative transcription factor 
binding sites. Ten CpGs are located in the enhancer element region, seven in the methylation-sensitive region (MSR) and 17 
in the repetitive element region. "+1" indicates the transcription start site. Lower case letters from 'a -to- l' represent different 
transcription factor binding sites [14,15]: a, inducer response motif; b, γ-IFN responsive element; c, CRE element; d, AP-2 ele-
ment; e, TPA-responsive element; f, STAT5-responsive enhancer; g, CCAT box; h, C-fos enhancer; i, 19 homologous repeats; 
j, three repeats; k, two repeats; l, GC box. Upper case letters from 'A -to- K' represent amplicons (not scaled to size) designed 
to detect different CpG sites.BMC Research Notes 2009, 2:104 http://www.biomedcentral.com/1756-0500/2/104
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2.18%) that was comparable to the minimal reaction-to-
reaction variation in bisulfite treatment as determined by
fluorescent probe based quantitative version of methyla-
tion-sensitive PCR (MSP, MethyLight assay) [18]. A touch-
down PCR approach has been recommended for
overcoming PCR biases in reactions using BST-DNA tem-
plate [12], but the reproducibility of touchdown PCR has
not been examined with BST-DNA. We found that touch-
down PCR helped to overcome problems with PCR prod-
uct specificity, and resulted in highly reproducible results
from PCR-to-PCR on different days (CV 1.63%).
In this study, the PRF1  methylation pattern identified
using both whole blood and PBMC DNAs from normal
subjects appeared similar throughout the promoter region
in terms of extremely high methylation in distal enhancer
region, variable methylation in the MSR, and progres-
sively declining methylation in the proximal promoter
region. Except CpG sites 5 and 15, the absolute levels of
methylation at each of these CpG sites, however, differed
between whole blood and PBMC DNAs, with higher
methylation levels obtained using whole blood DNA. We
have not investigated the factors that contribute to this
Reproducibility of bisulfite treatment determined using amplicon G Figure 2
Reproducibility of bisulfite treatment determined using amplicon G. Mean methylation level (%) ± SD for four CpG 
sites 18–21 are shown.BMC Research Notes 2009, 2:104 http://www.biomedcentral.com/1756-0500/2/104
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similar pattern but different levels in methylation along
the  PRF1  promoter between whole blood and PBMC
DNAs but it is likely to be related to differences in cell
types between these samples from the same subject. In a
previous study that used bisulfite sequencing followed by
cloning, CpG site 14 was found to be the most highly
methylated (> 50%) in the MSR of CD4+ T and CD8+ T
cells of normal subjects [5]. On the contrary, the most
highly methylated CpG site in the MSR in normal subjects
in this study was found to be CpG site 16 located 70 bases
away from CpG site 14. These differences may be related
to differences in the subjects, cell populations or quantita-
tive nature of the assays employed between the studies.
The pysosequencing assay described in this report is
highly suitable to quantify differences in the methylation
of PRF1 in the various sub-populations of cells in blood
from normal and subjects with chronic diseases of
immune dysfunction. Further, the study suggests that
blood drawn in PAXgene blood DNA tubes may be inap-
propriate for DNA methylation studies of genes with
immune function.
We have not compared the estimates of PRF1 methylation
determined by pyrosequencing with other method such as
MSP or combined bisulfite restriction analysis since our
reproducibility data agree with other reports supporting
the reliability of pyrosequencing for quantitative and effi-
cient screening of multiple CpG sites in candidate genes
studies [13,19-21]. Further, pyrosequencing has been
used as a reference method for validation of other meth-
Reproducibility of touchdown PCR determined using amplicon G Figure 3
Reproducibility of touchdown PCR determined using amplicon G. Mean methylation level (%) ± SD for four CpG 
sites 18 to 21 are shown.BMC Research Notes 2009, 2:104 http://www.biomedcentral.com/1756-0500/2/104
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ods and has been shown to have excellent specificity and
sensitivity for diagnostic uses [22,23]. A number of dilu-
tion and titration experiments with known amounts of
methylated and unmethylated DNA or cells with methyl-
ated viral DNA in the background of uninfected cells also
support the reliability of pyrosequencing for the sensitive
and specific determination of methylation at multiple
CpG sites [10,13,18,23,24].
Conclusion
In conclusion, we have developed a highly reproducible
procedure based on pyrosequencing technology for the
site-specific and quantitative determination of methyla-
tion levels in 32 CpG sites in the PRF1 promoter. In nor-
mal subjects, methylation levels along the 1.4 kb
promoter varied similarly in DNAs from whole blood and
PBMC but differed in absolute methylation levels, sug-
gesting collection of blood in devices like PAXgene blood
DNA tube may not be appropriate for methylation studies
of immune function related genes. This method can be
applied to clinical samples in order to systematically eval-
uate the significance of multiple CpG sites in perforin
which will improve our understanding of the pathophys-
iology of chronic disorders with alterations in immune
function.
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